Springhorn Jeremy P. sold $54K of QURE

Springhorn Jeremy P. sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · Springhorn Jeremy P.
Published Jun 12, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
high confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The only new fact is the director’s open-market sale details (shares, price, and post-transaction holdings).

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone does not change uniQure’s fundamentals.

03

What to watch

The absence of a stated 10b5-1 plan can increase speculation, but without additional context (e.g., prior planned sales, compensation structure) it’s not a reliable signal.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12; sale dated 2026-06-11

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralHigh confidence
Context

uniQure director Jeremy P. Springhorn sold 1,993 shares in an open-market transaction on 2026-06-11, per SEC Form 4.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with no accompanying company news (no guidance, trial, deal, or regulatory action) and no 10b5-1 plan disclosed.

Market effects

No clear read-through to the gene-therapy/biotech sector from a single director sale.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to typical institutional float and lacks any fundamental accompanying event, it may be driven by diversification or taxes rather than negative outlook.

Key entities

  • uniQure N.V.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Jeremy P. Springhorn

    Director who sold 1,993 shares on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.